At follow-up , STP patients had had a lower incidence of the primary endpoint , relative to controls ( @/@ vs. @/@ patients ; p = @ , respectively ; NNT = @ ) ; this benefit was attributable to the lower incidence of recurrent angina and of new comorbidities in the STP group ( @/@ vs. @/@ patients , p = @ , NNT = @ ; and @/@ vs. @/@ , p < @ , NNT = @ , respectively ) .